Study of CABA-201 for active myositis in adults and children
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment called CABA-201, which uses your own immune cells modified to attack the overactive cells causing myositis. It is for people with active disease that hasn't improved enough with standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 75 years old.
- You have a confirmed diagnosis of myositis (such as dermatomyositis, antisynthetase syndrome, or immune-mediated necrotizing myopathy).
- Your disease is still active despite trying usual treatments (like steroids or immunosuppressants).
- You have muscle weakness.
- You have not had a prior CAR T cell therapy or a transplant of an organ or blood-forming stem cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immune therapy called CAR T-cells (KYV-101) for people with active, tough-to-treat dermatomyositis. It aims to see if the treatment is safe and can reduce muscle weakness and skin rash.
This trial tests a new type of immune cell therapy (UCAR-T) that targets a protein called CD19 to treat children with a severe form of juvenile dermatomyositis that hasn't responded to standard treatments. It aims to calm the overactive immune system and reduce symptoms like muscle weakness and skin rashes.
This trial tests a new cell therapy called CABA-201 for people with generalized myasthenia gravis. It aims to reset the immune system to reduce muscle weakness and improve daily functioning.
This trial tests a new treatment called CABA-201, which is a type of immune cell therapy (CAR T cells) for people with active lupus. The goal is to see if it's safe and can help control lupus symptoms.
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
This trial tests a new treatment called Descartes-08 for people with dermatomyositis or antisynthetase syndrome whose disease hasn't responded well to standard therapies. It aims to see if this treatment can help control muscle and skin symptoms.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.